Ameya Laboratories Peer Comparison

BSE: 532981

₹0.24

₹0.00 (0.00%)

As on 16-Mar-2015IST

Market cap

₹6 Cr

Revenue (TTM)

₹160 Cr

P/E Ratio

--

P/B Ratio

--

Div. Yield

0 %

Edit

	Ameya Laboratories	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Market cap (₹ Cr)	6	30,606	30,088	28,551	25,816
Revenue (₹ Cr)	160	3,564	1,936	9,205	1,462
Net Profit (₹ Cr)	-19.78	414.00	288.22	-371.81	387.35
Net Margin (%)	-12.32	11.23	14.79	-3.93	26.01
RoE (%)	-12.38	8.38	29.77	-3.85	25.18
Price to Earnings	--	74.83	104.39	--	66.84
Price-To-Book	--	6.08	22.41	3.57	14.93

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Ameya Laboratories	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Operating Revenue	268.04	4,350.50	34.80	--	33.90
Total Income	268.62	4,375.84	34.80	--	34.61
Total Expenditure	228.49	2,996.79	25.65	--	30.42
EBITDA	39.55	1,353.71	9.15	--	3.48
Depreciation	7.68	115.07	2.71	--	1.05
EBIT	31.88	1,238.64	6.44	--	2.42
Interest	25.54	269.02	2.51	--	1.10
Other Income	0.58	25.34	0.42	--	0.71
Exceptional Items	-0.56	-473.77	--	--	--
Profit before Tax	6.35	521.19	3.93	--	2.03
Provision for Tax	2.91	221.74	1.40	--	0.68
Profit after Tax	3.44	299.45	2.52	--	1.35

Liabilities (₹ Cr)

	Ameya Laboratories	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Shareholder's Funds	165.42	1,471.02	37.49	--	6.11
Minority Interest	--	--	--	--	--
Non-Current Liabilities	54.07	2,891.88	5.39	--	0.04
Current Liabilities	114.49	1,890.94	24.92	--	15.82
Total Liabilities	333.98	6,253.84	67.79	--	22.09

Assets (₹ Cr)

	Ameya Laboratories	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Non-Current Assets	162.68	3,772.33	47.64	--	5.51
Current Assets	169.64	2,481.51	20.15	--	16.45
Total Assets	333.98	6,253.84	67.79	--	22.09
Total Debt*	130.84	3,492.50	19.14	--	6.41
Net Current Assets	55.15	590.57	-4.76	--	0.63
Contingent Liabilities	2.21	46.91	0.71	--	--

Cashflow (₹ Cr)

	Ameya Laboratories	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Cash From Operating Activities	-10.13	1,343.83	5.07	--	--
Cash Flow from Investing Activities	-18.93	-305.45	-4.60	--	--
Cash from Financing Activities	25.82	-826.56	-0.83	--	--
Net Cash Inflow / Outflow	-3.23	211.82	-0.36	--	0.00

Ratios

Profitability Ratios

	Ameya Laboratories	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
ROCE (%)	11.60	16.20	12.09	--	25.61
ROE (%)	2.13	66.74	14.65	--	24.87
ROA (%)	1.10	4.97	4.06	--	6.42
EBIT Margin (%)	14.97	31.70	26.29	--	12.34
Net Margin (%)	1.28	6.84	7.25	--	3.90
Cash Profit Margin (%)	3.97	9.52	15.04	--	6.56

Growth Ratios

	Ameya Laboratories	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Revenue Growth (%)	-1.70	15.97	65.29	--	21.86
EBIT Growth (%)	-13.09	29.05	42.04	--	27.63
Net Profit Growth (%)	-73.93	212.90	6.25	--	7.55
EPS Growth (%)	-73.93	278.36	6.25	--	7.55
Book Value Growth (%)	3.34	253.45	15.81	--	28.51

Valuation Ratios

	Ameya Laboratories	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Price / Earnings	12.44	17.64	0.00	--	0.00
Price / Book Value	0.26	9.37	0.00	--	0.00
Dividend Yield (%)	0.00	0.00	--	--	--
EV/EBITDA	4.24	7.33	4.36	--	1.71
Market Cap (₹ Cr)	42.78	6,555.46	0.00	--	0.00

Solvency Ratios

	Ameya Laboratories	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debt to Equity	0.80	2.39	0.51	--	1.05
Short term debt to equity ratio	0.44	0.18	0.21	--	0.88
Current Ratio	1.48	1.31	0.81	--	1.04
Quick Ratio	0.90	0.84	0.77	--	0.66
Interest Coverage	1.25	2.94	2.57	--	2.86

Operating Efficiency Ratios

	Ameya Laboratories	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debtors to sales (%)	31.10	17.44	42.51	--	24.27
Asset Turnover	0.90	0.72	0.56	--	1.74
Receivable days	90.31	57.17	120.33	--	81.45
Inventory Days	88.40	67.16	9.04	--	45.36
Payable days	12.65	116.25	535.25	--	134.63
Cash Conversion Cycle	166.07	8.07	-393.94	--	-7.82

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly